Poster zum Thema "Structural Proteomics"

Zurück
  • P-II-0559
LiP-MS guided drug discovery using the cancer driver Ras as a model system
  • P-II-0561
Aggrescan4D: structure-informed analysis of pH-dependent protein aggregation
  • P-II-0563
Structural analysis of a plant glucosyl ceramidase (GBA2)-like enzyme from arabidopsis thaliana by cryogenic electron microscopy (CRYO-EM)
  • P-II-0564
Natural inhibitors of snake venom toxins: a promising source of therapeutic peptides for toxin-centric next-generation antivenoms
  • P-II-0565
Optimized XL-MS workflows for heterobifunctional crosslinkers SDA and DizSEC
  • P-II-0566
Protein–RNA crosslinking combined with MS becomes quantitative at the peptide and amino-acid level
  • P-II-0567
The regulation role of host cell calmodulin in late phase of retroviral life cycle
  • P-II-0568
A novel cross-linking strategy for aromatic residues
  • P-II-0569
Fast FluoroAlkylation of Proteins (FFAP) as a new tool for characterization of protein therapeutics
  • P-II-0570
Quantitative assessment of protein structural changes and drug binding affinities using limited proteolysis mass spectrometry
  • P-II-0571
Fast photochemical oxidation of protein: DIA workflow and the impact of the peptide identification framework
  • P-II-0572
Structural proteomics of human serum proteins
  • P-II-0573
Unveiling hidden protein dynamics: a multi-proteomic approach to study new players in metastatic melanoma progression
  • P-II-0574
Trapped-ion mobility spectrometry with PASEF for analysis of RNA-protein crosslinks in Escherichia coli ribosomes and HeLa cell line nucleic extract
  • P-II-0575
Determination of M-PMV matrix protein-calmodulin interaction interface using hydrogen deuterium exchange mass spectrometry
  • P-II-0576
Investigation of protein dynamics in immortalized mouse macrophages stimulated by lipopolysaccharide (LPS) using limited proteolysis-coupled mass spectrometry
  • P-II-0577
A novel opportunities for the structural characterization of the biomolecular assemblies
  • P-II-0578
Novel, specific protein structural biomarkers for Alzheimer's disease and dementia with Lewy bodies
  • P-II-0579
In silico identification of potential inhibitors against Galectin-3-Binding Protein: A potent Key factor for glioma progression
  • P-II-0580
Use of singlet oxygen to analyze protein structure
  • P-II-0581
Advancements in LiP-MS: short-gradient LC-MS and automated sample preparation for improved drug target identification
  • P-II-0582
A multi-proteomics approach identifies non-catalytic effects of ATP-competitive kinase inhibition
  • P-II-0583
Deep proteomics reveals incorporation of unedited proteins into mitochondrial protein complexes in Arabidopsis
  • P-II-0585
Comparison of different glycoproteomics software of glycoproteomics including GRable, a new web-based software using a MS1-based glycopeptide detection method
  • P-II-0586
Photo-crosslinked peptide-RNA hybrids with tunable length map protein-RNA interfaces across the proteome and transcriptome
  • P-II-0587
Advancing Crosslinking Mass Spectrometry: Integrating Novel Data Acquisition Strategies and Enhanced Work-Up Techniques
  • P-II-0588
Multimodal mass spectrometry identifies a conserved protective epitope in S. pyogenes Streptolysin O
  • P-II-0589
A structural proteomics approach to quantify protein reorganization during TDP-43 liquid-to-solid phase transitions
  • P-II-0590
Structure and interactions of the endogenous human commander complex
  • P-II-0591
Structural proteomics for the development of thrombolytic drug
  • P-II-0592
Novel XL-MS analysis workflows for membrane protein characterization
  • P-II-0593
In vivo protein footprinting reveals the dynamic conformational changes of Proteome of multiple tissues in progressing Alzheimer's disease
  • P-II-0594
Structural mass spectrometry captures residue-resolved comprehensive conformational rearrangements of a G protein-coupled receptor